新闻
TTNP
--
0.00%
--
每日生物技术脉搏:Novavax首席财务官离职,Zai Lab与癌症药物合作,FDA授予Gilead点头
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 13)
Benzinga · 11小时前
每日生物技术脉动:阿玛琳的领导权过渡,强生公司的疫苗受挫,美国食品药品管理局提名罗氏哮喘药物的标签扩展
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 12)
Benzinga · 1天前
10-K:TITAN PHARMACEUTICALS INC
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 03/31 20:15
阿片类药物使用障碍市场规模,份额,增长,行业分析,机会和预测2019-2025
Mar 01, 2021 (Market Insight Reports) -- The global opioid use disorder market is estimated to witness significant growth during the forecast period...
Market Insight Reports · 03/01 10:31
立即购买的顶级竹enny股票? 4回调后的观看
Feb 25, 2021 (Penny Stocks via COMTEX) -- 4 Biotech Penny Stocks To Watch Heading Into March 2021 Like any good investor, the key to picking penny stocks to...
Penny Stocks · 02/25 18:43
分析师将买入的竹enny股票目标价为76%-209%
Feb 24, 2021 (Penny Stocks via COMTEX) -- Analysts Are Bullish On These 4 Penny Stocks We've discussed penny stocks and analyst ratings many times before....
Penny Stocks · 02/24 21:12
下周购买的最佳便士股票?您可能错过的5种生物技术
Feb 24, 2021 (Penny Stocks via COMTEX) -- 5 Biotech Penny Stocks to Watch in February 2021 With February in full swing, investors are still searching for the...
Penny Stocks · 02/24 21:11
英国阿片类药物使用障碍(Oud)市场份额,规模产业发展分析,全球趋势,增长因素,CAGR现状,主要参与者的行业见解和预测期(2021-2027)
Feb 22, 2021 (Heraldkeepers) -- Pre & Post Covid-19 Impact and Recovery Analysis (Estimates) is Covered in Opioid Use Disorder (Oud) Market Research...
Heraldkeepers · 02/22 10:55
Maxim Group宣布DJ Titan Pharmaceuticals目标股价为11.00美元/股
Dow Jones · 02/18 12:42
Maxim Group提出将DJ Titan Pharmaceuticals的股票评级从“持有”调升为“买进”
Dow Jones · 02/18 12:42
Addictions Therapeutics市场规模,按趋势分析,增长状况,到2025年的收入期望,按趋势分析的2021年份额变动,市场报告世界的研究报告
The Express Wire · 02/18 06:11
Hypothyroidism Drug Market Research by Size 2021: Regional Analysis with Top Countries Data, Business Opportunities, Key Manufactures and Forecast to 2025
Feb 08, 2021 (The Expresswire) -- Global “Hypothyroidism Drug Market” 2021 research report represents a detailed overview of the current market situation and...
The Express Wire · 02/09 04:22
8-K:TITAN PHARMACEUTICALS INC
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT (EDGAR Online via COMTEX) -- Pursuant to Section 13 or 15(d)...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/04 23:34
全球阿片类药物使用障碍市场,规模,份额,分析报告和至2025的预测
Market Insight Reports · 02/03 09:28
DJ Titan Pharmaceuticals因瘙痒症治疗研究股价上涨8%
Dow Jones · 02/01 18:17
DJ Titan Pharmaceuticals从瘙痒症治疗研究中获得积极数据
Dow Jones · 02/01 14:22
BRIEF-Positive Early Study Results Help Pave Wave For Titan Pharmaceuticals To Move Forward With Its JT-09 ProNeura Development Program
reuters.com · 02/01 12:37
Titan Pharmaceuticals对其Kappa阿片类激动剂肽JT-09进行了研究,“证明了其对人Kappa类阿片受体的高效性和特异性”
SOUTH SAN FRANCISCO, Calif., Feb. 1, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced that studies of its kappa opioid agonist peptide, JT-09, has demonstrated high potency
Benzinga · 02/01 12:35
到2027年,成瘾治疗市场的复合年增长率将达到6.2%
Jan 30, 2021 (Market Insight Reports) -- Addiction Treatment market is expected to gain market growth in the forecast period of 2020 to 2027.nova one advisor...
Market Insight Reports · 01/30 20:50
S-1:TITAN PHARMACEUTICALS INC
(EDGAR Online via COMTEX) -- As filed with the Securities and Exchange Commission on January 27, 2021 Registration No. 333-_______ UNITED STATES SECURITIES...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 01/27 23:13
微牛提供丰富的实时TTNP股票新闻,让你可以通过多个平台了解TTNP股票行情最新动态,这些免费的Titan制药新闻可以帮助你做出明智投资。
TTNP 简况
Titan Pharmaceuticals Inc(Titan)是一家专业制药公司。该公司从事医学疾病疗法的开发业务。该公司的部门从事药品开发业务。该公司的产品开发计划利用了其长期药物递送平台ProNeura。该公司正处于开发阶段的候选药物Probuphine用于阿片依赖的长期维持治疗。Titan的ProNeura连续药物递送系统由一种由乙烯-乙酸乙烯酯(EVA)和一种原料药混合物制成的小实心棒组成。该公司专注于开发两个产品开发项目,第一个是用于治疗帕金森病(PD)的罗匹尼罗植入物,第二个是用于治疗甲状腺机能低下症的三碘甲腺原氨酸(T3)植入物。